The stock of RepliCel Life Sciences Inc (CVE:RP) is a huge mover today! About 22,000 shares traded hands or 84.98% up from the average. RepliCel Life Sciences Inc (CVE:RP) has risen 6.00% since October 29, 2016 and is uptrending. It has underperformed by 0.01% the S&P500.
The move comes after 9 months negative chart setup for the $10.98M company. It was reported on Nov, 28 by Barchart.com. We have $0.79 PT which if reached, will make CVE:RP worth $329,400 less.
More important recent RepliCel Life Sciences Inc (CVE:RP) news were published by: Marketwired.com which released: “RepliCel Life Sciences Announces Closing of Private Placement” on October 31, 2016, also Midasletter.com published article titled: “RepliCel Life Sciences Inc. CEO David Hall Interview and Podcast”, Prnewswire.com published: “RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype” on July 29, 2015. More interesting news about RepliCel Life Sciences Inc (CVE:RP) was released by: Marketwired.com and their article: “RepliCel Announces CEO Update” with publication date: February 16, 2016.
RepliCel Life Sciences Inc. is a regenerative medicine firm focused on developing autologous cell therapies that treat functional cellular deficits. The company has a market cap of $10.98 million. The Company’s product pipeline includes RCT-01-Tendon Repair, RCS-01-Skin Rejuvenation, RCH-01-Hair Regeneration and RCI-02-Dermal Injector. It currently has negative earnings. RCT-01 is an autologous cell treatment utilizing non-bulbar dermal sheath cells isolated from the hair follicle sheath to treat chronic tendinosis caused by acute and chronic tensile overuse.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.